[1] 中华医学会肝病学分会. 肝硬化诊治指南[J]. 中华肝脏病杂志, 2019,27(11): 846-865. [2] Piano S, Cardenas A. Metabolomics to predict acute kidney injury in cirrhosis.[J]. Hepatology, 2021,74(5): 2339-2341. [3] Wong F, Reddy K R, Tandon P, et al. Progression of stage 2 and 3 acute kidney injury in patients with decompensated cirrhosis and ascites.[J]. Clin Gastroenterol Hepatol, 2021,19(8): 1661-1669. [4] Zanetto A, Rinder H M, Campello E, et al. Acute kidney injury in decompensated cirrhosis is associated with both hypo-coagulable and hyper-coagulable features.[J]. Hepatology, 2020,72(4): 1327-1340. [5] Desai A P, Knapp S M, Orman E S, et al. Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis-a US population-based study.[J]. J Hepatol, 2020,73(5): 1092-1099. [6] 庞国菊, 武玉晶, 刘爽, 等. 肝硬化继发急性肾损伤患者血清胱抑素C和中性粒细胞明胶酶相关脂质运载蛋白的水平及其诊断价值[J]. 中华肝脏病杂志, 2019,27(1): 65-67. [7] 柯坤宇, 潘晨, 陈丽芳, 等. 尿肾损伤分子-1对慢加急性(亚急性)肝功能衰竭患者并发急性肾损伤的早期诊断价值[J]. 中华传染病杂志, 2018,36(10): 627-629. [8] Huelin P, Solà E, Elia C, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study.[J]. Hepatology, 2019,70(1): 319-333. [9] Yao Q, Chen W, Yan C, et al. Efficacy and safety of treatments for patients with portal hypertension and cirrhosis: a systematic review and bayesian network meta-analysis.[J]. Front Med (Lausanne), 2021,8: 712918. [10] Engelmann C, Clària J, Szabo G, et al. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.[J]. J Hepatol, 2021,75 Suppl 1(Suppl 1): S49-S66. [11] Nevens F, Bittencourt P L, Coenraad M J, et al. Recommendations on the diagnosis and initial management of acute variceal bleeding and hepatorenal syndrome in patients with cirrhosis.[J]. Dig Dis Sci, 2019,64(6): 1419-1431. [12] Cárdenas A, Ginès P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis.[J]. Hepatology, 2001,34(4 Pt 1): 671-676. [13] Zanetto A, Rinder H M, Campello E, et al. Acute kidney injury in decompensated cirrhosis is associated with both hypo-coagulable and hyper-coagulable features[J]. Hepatology, 2020,72(4): 1327-1340. [14] Desai A P, Knapp S M, Orman E S, et al. Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis - a US population-based study[J]. J Hepatol, 2020,73(5): 1092-1099. [15] 庞国菊, 武玉晶, 刘爽, 等. 肝硬化继发急性肾损伤 患者血清胱抑素C和中性粒细胞明胶酶相关脂质运载蛋白的水平及其诊断价值[J]. 中华肝脏病杂志, 2019,27(1): 65-67. [16] 柯坤宇, 潘晨, 陈丽芳, 等. 尿肾损伤分子-1对慢加急性(亚急性)肝功能衰竭患者并发急性肾损伤的早期诊断价值[J]. 中华传染病杂志, 2018,36(10): 627-629. [17] Huelin P, Solà E, Elia C, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study[J]. Hepatology, 2019,70(1): 319-333. [18] Tariq R, Hadi Y, Chahal K, et al. Incidence, mortality and predictors of acute kidney injury in patients with cirrhosis: a systematic review and meta-analysis[J]. Journal of clinical and translational hepatology, 2020,8(2): 135-142. [19] Yao Q, Chen W, Yan C, et al. Efficacy and safety of treatments for patients with portal hypertension and cirrhosis: a systematic review and bayesian network meta-analysis[J]. Front Med (Lausanne), 2021,8: 712918. [20] Engelmann C, Clària J, Szabo G, et al. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction[J]. J Hepatol, 2021,75 Suppl 1(Suppl 1): S49-S66. [21] Nevens F, Bittencourt P L, Coenraad M J, et al. Recommendations on the diagnosis and initial management of acute variceal bleeding and hepatorenal syndrome in patients with cirrhosis[J]. Dig Dis Sci, 2019,64(6): 1419-1431. [22] Cárdenas A, Ginès P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis[J]. Hepatology, 2001,34(4 Pt 1): 671-676. |